AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have symptomatic, inoperable plexiform neurofibromas, or PN. Topline results showed that Koselugo demonstrated a statistically significant and clinically meaningful improvement in objective response rate, the study’s primary endpoint, versus placebo, in these adult patients. Neurofibromatosis type 1 is a rare, progressive genetic condition affecting an estimated 1.7 million people worldwide, approximately 70% of whom are adults. There are no approved treatments for adults. The safety profile of Koselugo in this study was consistent with that observed in clinical trials among children and adolescents. No new safety signals were identified. Alexion, AstraZeneca Rare Disease will share these data with regulatory authorities and present these data at a forthcoming medical meeting. AstraZeneca and Merck are jointly developing and commercializing Koselugo globally.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- AstraZeneca announces Koselugo met primary endpoing in KOMET Phase III trial
- Citius Pharmaceuticals, Citius Oncology report promising cancer trial results
- Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
- Merck price target lowered to $140 from $145 at Deutsche Bank
- Merck price target lowered to $130 from $137 at Guggenheim
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
